Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard.

Wood JM, Major D, Heath A, Newman RW, Höschler K, Stephenson I, Clark T, Katz JM, Zambon MC.

Vaccine. 2012 Jan 5;30(2):210-7. doi: 10.1016/j.vaccine.2011.11.019. Epub 2011 Nov 17.

PMID:
22100887
2.

Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines-an effective EU regulatory approach.

Wagner R, Göpfert C, Hammann J, Neumann B, Wood J, Newman R, Wallis C, Alex N, Pfleiderer M.

Vaccine. 2012 Jun 8;30(27):4113-22. doi: 10.1016/j.vaccine.2012.02.077. Epub 2012 Mar 22.

PMID:
22446639
3.

Comparison of influenza serological techniques by international collaborative study.

Wood JM, Gaines-Das RE, Taylor J, Chakraverty P.

Vaccine. 1994 Feb;12(2):167-74.

PMID:
8147099
4.

Calibration of the Ph. Eur. Biological Reference Preparation (BRP) for tetanus vaccine (adsorbed) batch 3.

Tierney R, Hockley J, Rigsby P, Terao E, Daas A, Buchheit KH, Sesardic D.

Pharmeur Bio Sci Notes. 2011 Jun;2011(1):1-26.

PMID:
21619853
5.

Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.

Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.

Vaccine. 2011 Sep 16;29(40):6888-93. doi: 10.1016/j.vaccine.2011.07.050. Epub 2011 Jul 29.

PMID:
21803100
6.

Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study.

Stephenson I, Das RG, Wood JM, Katz JM.

Vaccine. 2007 May 16;25(20):4056-63. Epub 2007 Feb 27.

PMID:
17412461
7.

Reproducibility of serologic assays for influenza virus A (H5N1).

Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, Katz JM, Weir JP, Zambon MC, Wood JM.

Emerg Infect Dis. 2009 Aug;15(8):1252-9. doi: 10.3201/eid1508.081754.

8.

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.

Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I.

Vaccine. 2010 Apr 19;28(18):3076-9. doi: 10.1016/j.vaccine.2010.02.050. Epub 2010 Mar 1.

PMID:
20193791
9.

Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.

Rudenko L, van den Bosch H, Kiseleva I, Mironov A, Naikhin A, Larionova N, Bushmenkov D.

Vaccine. 2011 Jul 1;29 Suppl 1:A40-4. doi: 10.1016/j.vaccine.2011.04.122. Review.

10.

Monoclonal antibodies to the haemagglutinin HA1 subunit of the pandemic influenza A/H1N1 2009 virus and potential application to serodiagnosis.

Samuel D, Warrener L, Hoschler K.

J Med Virol. 2011 Apr;83(4):559-67. doi: 10.1002/jmv.21982.

PMID:
21328368
11.

Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.

Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D.

Vaccine. 2011 Dec 9;30(1):35-41. doi: 10.1016/j.vaccine.2011.10.062. Epub 2011 Nov 7.

PMID:
22063386
12.
13.

Collaborative study on influenza vaccine clinical trial serology - part 1: CHMP compliance study.

Wood JM, Newman RW, Daas A, Terao E, Buchheit KH.

Pharmeur Bio Sci Notes. 2011 Jun;2011(1):27-35.

PMID:
21619854
14.

Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.

Zhu H, Ding X, Chen X, Yao P, Xu F, Xie R, Yang Z, Liang W, Zhang Y, Li Y, Shen J, He P, Guo Z, Su B, Sun S, Zhu Z.

Vaccine. 2011 Jul 26;29(33):5421-3. doi: 10.1016/j.vaccine.2011.05.067. Epub 2011 Jun 7.

PMID:
21645575
15.

Cross-reaction but no avidity change of the serum antibody response after influenza vaccination.

Brokstad KA, Cox RJ, Major D, Wood JM, Haaheim LR.

Vaccine. 1995 Nov;13(16):1522-8.

PMID:
8578836
16.

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.

Vaccine. 2010 Feb 17;28(7):1740-5. doi: 10.1016/j.vaccine.2009.12.014. Epub 2009 Dec 22.

PMID:
20034605
17.

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM.

N Engl J Med. 2009 Nov 12;361(20):1945-52. doi: 10.1056/NEJMoa0906453. Epub 2009 Sep 10.

18.

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers.

Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, Nilsen M, Mohn K, Jul-Larsen A, Smith I, Major D, Wood J, Cox RJ.

Vaccine. 2010 Dec 16;29(2):266-73. doi: 10.1016/j.vaccine.2010.10.038. Epub 2010 Oct 27.

PMID:
21034828
19.

The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.

Engelhard D, Zakay-Rones Z, Shapira MY, Resnick I, Averbuch D, Grisariu S, Dray L, Djian E, Strauss-Liviatan N, Grotto I, Wolf DG, Or R.

Vaccine. 2011 Feb 17;29(9):1777-82. doi: 10.1016/j.vaccine.2010.12.113. Epub 2011 Jan 7.

PMID:
21216315
20.

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R.

Virus Res. 2004 Jul;103(1-2):163-71.

PMID:
15163505

Supplemental Content

Support Center